Novel genes detected by transcriptional profiling from whole-blood cells in patients with early onset of acute coronary syndrome

Abstract

Transcriptomic analysis by microarray technology demonstrated differential expression during a 48 h time course suggesting a potential use of some of these genes as biomarkers for very early stages of ACS, as well as for monitoring early cardiac ischemic recovery.

Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction

“…Statistically, these differences are suggestive and do not pass a strict Bonferroni correction for multiple testing. However, we do provide support for the increased expression of KCNE1 (p=0.00793) and ECHDC3 (p=0.0141) as well as decreased expression of MIAT (p=0.0449) in STEMI platelets compared to NSTEMI, as previously reported in whole blood, as well as increased expression of FKBP5 (p=0.000694) in platelets from STEMI patients (Table IIIb, Table IV) [21-23]. Our observation of increased MYL4 expression in NSTEMI compared to STEMI platelets is in the opposite direction as previously reported [21].…”

“…However, we do provide support for the increased expression of KCNE1 (p=0.00793) and ECHDC3 (p=0.0141) as well as decreased expression of MIAT (p=0.0449) in STEMI platelets compared to NSTEMI, as previously reported in whole blood, as well as increased expression of FKBP5 (p=0.000694) in platelets from STEMI patients (Table IIIb, Table IV) [21-23]. Our observation of increased MYL4 expression in NSTEMI compared to STEMI platelets is in the opposite direction as previously reported [21]. Pathway analyses of suggestively differentially expressed genes (p≤0.05) showed enrichment for metabolic and mitochondrial-related pathways, including the synthesis of metabolic enzymes (panthothenate and CoA) and metabolism of nucleotide sugars, amino acids, and glycerophospholipids (Supplemental Tables 14-17).…”

“…However, little is known regarding the roles platelets may play in differences between STEMI and NSTEMI subtypes. Previous studies examining expression differences between STEMI and NSTEMI cases in whole blood showed that ECHDC3 and KCNE1 are differentially higher expressed and MIAT lower expressed, respectively [21,22]. We provide support for these expression differences with the same direction of effect in platelets.…”

“…These differences in platelet reactivity and disease progression may result from gene expression differences between STEMI and NSTEMI cases. Previous studies in whole blood identified several differentially expressed transcripts between STEMI and NSTEMI cases including KCNE1 , ECHDC3 , and MIAT [21,22]. Another study identified 54 differentially expressed transcripts in platelets between STEMI and stable coronary artery disease (CAD) patients, with CD69 and S100A9 being the strongest candidates [23].…”

The relationship of the oleic acid level and ECHDC3 mRNA expression with the extent of coronary lesion

“…In a microarray-based gene expression study performed previously by our research team, we found that ECHDC3 mRNA expression was significantly increased within 2 h after an acute coronary syndrome, suggesting this gene could be a potential novel biomarker for the early stage of an acute episode [3]. However, the function of ECHDC3 or its involvement with cardiovascular diseases is scarcely explored in the literature, which might be due to its recent identification.…”